{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:28:19Z","timestamp":1791599299066,"version":"4.3.4"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Lipoprotein(a) (Lp(a)) is a genetically determined independent risk factor for cardiovascular disease and calcific aortic stenosis; thus, serum levels are minimally affected by conventional treatments for hypercholesterolemia and hypertriglyceridemia. New RNA therapies directly targeting Lp(a) have demonstrated efficacy in decreasing serum levels. Several recent trials have demonstrated efficacy and safety of these RNA therapeutics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Single-stranded antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) are two classes of RNA-targeted therapeutics that specifically target the <jats:italic toggle=\"yes\">LPA<\/jats:italic> gene, which encodes for apolipoprotein(a), a dominant and rate-limiting component in the hepatic synthesis of Lp(a) particle. Pelacarsen (ASO), olpasiran (siRNA) and SLN360 (siRNA) are novel drugs that have demonstrated efficacy in lowering Lp(a) levels and excellent safety profiles.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Lp(a) is an independent risk factor for cardiovascular disease. RNA-directed therapies, pelacarsen, olpasiran and SLN360, have shown efficacy in dramatically lowering serum Lp(a) levels. Outcomes data will be the next frontier of Lp(a) trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000856","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T06:00:14Z","timestamp":1667887214000},"page":"301-308","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Recent lipoprotein(a) trials"],"prefix":"10.1097","volume":"33","author":[{"given":"Trent","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"European Prospective Investigation Into Cancer and Nutrition\u2013Cardiovascular Disease Consortium. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1194\/jlr.R053066","article-title":"Current therapies for lowering lipoprotein (a)","volume":"57","author":"van Capelleveen","year":"2016","journal-title":"J Lipid Res"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jacc.2008.02.066","article-title":"Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study","volume":"52","author":"Choi","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2009.02.041","article-title":"MIRACL Study Investigators. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial","volume":"53","author":"Fraley","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","article-title":"Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients","volume":"35","author":"Croyal","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"ACCELERATE Investigators. Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE Trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1194\/jlr.P027235","article-title":"Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia","volume":"53","author":"Arai","year":"2012","journal-title":"J Lipid Res"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"ODYSSEY OUTCOMES Committees and Investigators. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R22-20250729","first-page":"673","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nature Rev"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomized, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O\u2019Donoghue","year":"2022","journal-title":"Am Heart J"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:09:17Z","timestamp":1753826957000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000856","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}